Gilder Gagnon Howe & Co. LLC grew its position in Livongo Health (NASDAQ:LVGO) by 87.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,676,694 shares of the company’s stock after purchasing an additional 783,726 shares during the period. Livongo Health comprises about 1.0% of Gilder Gagnon Howe & Co. LLC’s portfolio, making the stock its 27th largest position. Gilder Gagnon Howe & Co. LLC owned about 1.67% of Livongo Health worth $126,071,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Evoke Wealth LLC purchased a new stake in Livongo Health during the first quarter worth about $28,000. PNC Financial Services Group Inc. increased its holdings in Livongo Health by 285.3% during the first quarter. PNC Financial Services Group Inc. now owns 1,541 shares of the company’s stock worth $44,000 after buying an additional 1,141 shares during the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new stake in Livongo Health during the second quarter worth about $47,000. Watson Rebecca purchased a new stake in Livongo Health during the second quarter worth about $53,000. Finally, IFP Advisors Inc increased its holdings in Livongo Health by 39.3% during the second quarter. IFP Advisors Inc now owns 805 shares of the company’s stock worth $57,000 after buying an additional 227 shares during the last quarter. Institutional investors own 41.67% of the company’s stock.
In other Livongo Health news, President Jennifer Schneider sold 13,400 shares of Livongo Health stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $74.30, for a total transaction of $995,620.00. Also, insider James Pursley sold 24,857 shares of Livongo Health stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $74.37, for a total transaction of $1,848,615.09. Following the sale, the insider now owns 98,889 shares of the company’s stock, valued at $7,354,374.93. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 733,716 shares of company stock valued at $88,964,053. 13.00% of the stock is currently owned by company insiders.
A number of analysts recently issued reports on LVGO shares. ValuEngine downgraded shares of Livongo Health from a “buy” rating to a “hold” rating in a report on Wednesday, July 22nd. Citigroup lifted their target price on shares of Livongo Health from $125.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Stephens started coverage on shares of Livongo Health in a research note on Monday, July 6th. They issued an “overweight” rating and a $95.00 target price for the company. JPMorgan Chase & Co. lifted their target price on shares of Livongo Health from $36.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, May 22nd. Finally, Needham & Company LLC downgraded shares of Livongo Health from a “buy” rating to a “hold” rating in a research note on Thursday, August 6th. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Livongo Health has a consensus rating of “Buy” and an average price target of $90.11.
Shares of LVGO stock traded down $2.51 during trading hours on Friday, reaching $126.49. The stock had a trading volume of 3,031,481 shares, compared to its average volume of 3,495,317. The stock’s fifty day simple moving average is $124.39 and its 200 day simple moving average is $67.10. The company has a current ratio of 19.88, a quick ratio of 19.51 and a debt-to-equity ratio of 0.69. Livongo Health has a 12 month low of $15.12 and a 12 month high of $150.00. The firm has a market capitalization of $12.69 billion, a PE ratio of -308.50 and a beta of 1.75.
Livongo Health (NASDAQ:LVGO) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.17. Livongo Health had a negative net margin of 12.76% and a negative return on equity of 4.86%. The company had revenue of $91.90 million during the quarter, compared to analyst estimates of $86.68 million. During the same period last year, the business earned ($0.46) earnings per share. Livongo Health’s revenue was up 124.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Livongo Health will post -0.37 EPS for the current fiscal year.
Livongo Health Profile
Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.
Featured Article: Technical Analysis
Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.